Designed For Prolonged Exposure1,2
ONIVYDE® (irinotecan liposome injection) is an encapsulation of irinotecan in a long-circulating liposome
- The half-life (T1/2) of total irinotecan following administration of ONIVYDE® 70 mg/m2 is 25.8 hours
- 95% of irinotecan remains contained within the liposome during circulation
- The ratio between total and encapsulated forms did not change from 0 to 169.5 hours post-dose
- In mice bearing human tumor xenografts, ONIVYDE® achieved similar intratumoral exposure of SN-38 at a 5-fold lower dose than irinotecan HCl
HCl=hydrochloride; PEG-DSPE=polyethylene glycol-distearoylphosphatidylethanolamine.